Ismo Mattila

Research scientist,
Systems Medicine


Mobile: +45 30 91 33 43

Research area

Analysing  biological samples using mass spectrometric methods, using UHPLC-QTOF for analysing lipidomics samples. In addition also untargeted global metabolomics samples using GC×GC-TOF instrument.

Current research

1. Galaxy
GALAXY has the ambition, by combining unique capabilities in European institutions, to perform integrated systems modelling of multi-omics data together with clinical data. To improve understanding of alcoholic liver fibrosis, and to develop diagnostic, prevention and treatment programs.
Read more on the website of the project

2. Microbliver
The portal vein transports metabolites produced by the human gut microbiota directly to the liver, and these may play a role in developing several liver diseases. The project will have access to many patients and will comprehensively screen their microbiota, liver and blood. The goal is to build models that describe the gut microbiome–portal vein–liver axis and to identify biomarkers for predicting, preventing and treating metabolic liver diseases

3. Innodia

The overall objective of INNODIA therefore is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D), by creating novel tools, such as biomarkers, disease models and clinical trial paradigms.
Read more on the website of the project

4. Rhapsody

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
Read more on the website of the project

PeRsOnalising Treatment Of diabetic Nephropathy
Diabetes er ofte forbundet med nedsat nyrefunktion, en komplikation som kan udvikle sig til nyresvigt, og hvortil ingen effektiv behandling findes. I et internationalt samarbejde foreslås state-of-the-art screening af en lang række biologiske markører i blod, urin og tarmflora i patienter med nedsat nyrefunktion. Ved at sammenstille disse med raske i store internationale databaser vil det være muligt at forudsige og evaluere sygdomsrisici på en personlig basis og dermed tillade en langt mere målrettet og personlig behandling, sandsynligvis med hidtil uset effektivitet.